Zoomed Image
  • Ziak 5mg/6.25mg  Tablets 30's

Ziak 5mg/6.25mg Tablets 30's

ZIAK is a combination of two antihypertensive agents, bisoprolol and hydrochlorothiazide. Bisoprolol is a beta 1-selective beta-adrenoceptor antagonist with low beta 2-receptor affinity. It has no intrinsic sympathomimetic activity nor membrane-stabilising properties. It reduces blood pressure, and by blockade of the cardiac beta 1-receptors, reduces the heart rate and depresses plasma renin levels. Bisoprolol is rapidly absorbed after oral administration in man and excreted predominantly via the urine as unaltered substance and metabolites. In man, 50% of a dose is metabolised in the liver while the other 50% is eliminated unchanged via the kidneys. None of the metabolites have beta 1-receptor blocking action. The plasma elimination half-life is 10-12 hours, resulting in a duration of action of 24 hours. Because of its moderate hepatic metabolism, it is subject only to a very small hepatic first pass metabolism. Therefore, bisoprolol displays a high bioavailability of 90% after an oral dose. Hydrochlorothiazide is a benzothiadiazine diuretic. Thiazides inhibit sodium and chloride reabsorption in the kidney tubules and produce a corresponding increase in potassium excretion. It is readily absorbed from the gastro-intestinal tract. It is reported to have a bioavailability of about 65 to 70%; the plasma half-life is about 5 hours with a subsequent longer terminal phase; its biological half-life is up to about 15 hours. It is excreted unchanged in the urine. ZIAK is indicated for the treatment of hypertension.
How to use
Antihypertensive therapy may be initiated with the lowest dose of ZIAK, one 2.5 mg/6.25 mg tablet once daily. Subsequent dose adjustment may be carried out with ZIAK tablets up to the maximum recommended dose of one 10 mg/6.25 mg tablet once daily, as appropriate. Dosage adjustment on the basis of age is not usually necessary, unless there is also significant renal or hepatic dysfunction. There is no paediatric experience with ZIAK. If withdrawal of ZIAK therapy is planned, it should be achieved gradually over a period of about 2 weeks. Patients should be carefully observed.
CONTRA-INDICATIONS:-Hypersensitivity to any component of this product or other sulphonamide derived agent. -Uncontrolled cardiac failure excluding that due to hypertrophic obstructive cardiomyopathy. -Patients with metabolic acidosis and sinus bradycardia. -Patients suffering from second and third degree heart block. -Bisoprolol should be given with caution, when there is no alternative treatment, to patients with bronchospasm or asthma or to those with a history of obstructive airways disease. -Renal insufficiency (anuria, acute renal failure, severe progressive renal disease and diabetic nephropathy). -Not to be used during pregnancy or lactation.